title: Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease.
abstract: OBJECTIVE
  To investigate striatal adenosine A2A receptor availability in patients with Parkinson disease (PD) with and without levodopa-induced dyskinesias (LIDs). While providing effective relief from the motor symptoms of PD, chronic levodopa use is associated with development of LIDs. A2A receptors are expressed on the bodies of indirect pathway medium spiny striatal neurons and on dopamine terminals and play a role in modulating dopamine transmission. A2A antagonists have antiparkinsonian activity by boosting levodopa efficacy. We aimed to study A2A receptor availability in patients with PD with and without LIDs using PET and [¹¹C]SCH442416, an A2A antagonist.
  
  
  METHODS
  Six patients with PD with and 6 without LIDs were studied withdrawn 12 hours from medication. Their PET findings were compared with 6 age-matched healthy controls. Using spectral analysis, [¹¹C]SCH442416 regional volumes of distribution (V(T)) were computed for the caudate, putamen, and thalamus and binding potentials (BP(ND)) reflecting the ratio of specific:nonspecific uptake were compared between groups.
  
  
  RESULTS
  A2A binding in the caudate and putamen of subjects with PD with LIDs was far higher (p = 0.026 and p = 0.036, respectively) than that of subjects with PD without LIDs, which lay within the control range. Thalamic A2A availability was similar for all 3 groups.
  
  
  CONCLUSIONS
  Patients with PD with LIDs show increased A2A receptor availability in the striatum. This finding is compatible with altered adenosine transmission playing a role in LIDs and provides a rationale for a trial of A2A receptor agents in the treatment of these motor complications.
authors: Room 244, Cyclotron Building, Hammersmith Hospital, Du Cane Road, London W120NN, UK. a.ramlackhansingh@imperial.ac.uk
authors: A F
authors: AF
authors: Ramlackhansingh
authors: S K
authors: SK
authors: Bose
authors: I
authors: I
authors: Ahmed
authors: F E
authors: FE
authors: Turkheimer
authors: N
authors: N
authors: Pavese
authors: D J
authors: DJ
authors: Brooks
references: Synapse. 1997 Dec;27(4):322-35
references: 9372555
references: J Pharmacol Exp Ther. 2009 Jul;330(1):294-303
references: 19332567
references: Prog Neurobiol. 1999 Nov;59(4):355-96
references: 10501634
references: Expert Opin Investig Drugs. 2005 Jun;14(6):729-38
references: 16004599
references: Neurology. 2003 Aug 12;61(3):297-303
references: 12913187
references: Ann Neurol. 2008 Mar;63(3):295-302
references: 18306243
references: J Med Chem. 2000 Nov 16;43(23):4359-62
references: 11087559
references: Mov Disord. 2005 Aug;20(8):919-31
references: 16007614
references: Neuroreport. 1998 Aug 24;9(12):2857-60
references: 9760134
references: Mov Disord. 2001 May;16(3):448-58
references: 11391738
references: Parkinsonism Relat Disord. 2006 Dec;12(8):499-505
references: 16935018
references: Parkinsonism Relat Disord. 2010 Jan;16(1):16-20
references: 19616987
references: Brain. 2004 May;127(Pt 5):1075-84
references: 15033896
references: Parkinsonism Relat Disord. 2010 Jul;16(6):423-6
references: 20338800
references: J Cereb Blood Flow Metab. 2007 Sep;27(9):1533-9
references: 17519979
references: Eur J Nucl Med Mol Imaging. 2005 Apr;32(4):405-13
references: 15549298
references: Mov Disord. 2010 Jul 30;25(10):1437-43
references: 20629136
references: Curr Pharm Des. 2008;14(15):1468-74
references: 18537670
references: J Nucl Med. 1997 Oct;38(10):1614-23
references: 9379202
references: J Cereb Blood Flow Metab. 1994 May;14(3):406-22
references: 8163583
references: Eur J Neurosci. 2009 Sep;30(5):823-32
references: 19712101
references: Neurobiol Dis. 2007 Jul;27(1):11-23
references: 17499513
references: J Cereb Blood Flow Metab. 1993 Jan;13(1):15-23
references: 8417003
references: Eur J Neurosci. 2000 Mar;12(3):1096-104
references: 10762340
references: J Cereb Blood Flow Metab. 1999 Nov;19(11):1189-208
references: 10566965
references: Arch Neurol. 2009 Nov;66(11):1353-8
references: 19901166
references: Neuroimage. 2006 Oct 15;33(1):115-26
references: 16860573
references: J Neuropathol Exp Neurol. 2002 Feb;61(2):186-96
references: 11853020
references: Med Phys. 1997 Jan;24(1):25-35
references: 9029539
references: Parkinsonism Relat Disord. 2009 Jul;15(6):406-13
references: 19446490